Cell Therapy Human Raw Materials Market (2024 - 2030) Size, Share & Trends Analysis Report, By Product (Cell Culture Media, Cell Culture Sera, Cell Culture Supplements), By End Use, By Region, And Segment Forecasts

Cell Therapy Human Raw Materials Market Summary

The COVID-19 pandemic had a significant impact on the market. One of the primary challenges stemmed from the widespread disruption of supply chains and manufacturing processes. The intricate network involved in the production of cell-based therapies relies heavily on the seamless flow of raw materials, and the pandemic-induced disruptions led to shortages and delays in manufacturing timelines. Lockdowns and travel restrictions hindered the transportation of raw materials, causing disruptions in the availability of critical components. In addition, the pandemic-induced disruptions had a ripple effect on research and clinical trials related to cell therapies. Many ongoing projects were temporarily halted or experienced significant slowdowns. 

The increasing adoption of regenerative medicine has become a driving force behind the growing field of cell therapy, impelling the demand for specific human raw materials essential to the innovative medical approach. Regenerative medicine, which emphasizes harnessing the body's healing capabilities and using cell-based therapies to address various diseases, has garnered widespread attention & support. This heightened interest stems from the potential to revolutionize treatment methodologies and provide novel solutions for conditions with limited therapeutic options.

In October 2023, the California Institute of Regenerative Medicine (CIRM) granted USD 2 million to the Keck School of Medicine of USC to enhance its recently established cGMP Laboratory. This state-of-the-art facility is designed to advance early-stage research into clinically viable cell & gene therapies. The funds from the CIRM grant are expected to support the development of advanced technological capabilities, streamlined operations, and rigorous protocols necessary for the efficient translation of these therapies from the laboratory to clinical applications. Similarly, in August 2023, the California Institute for Regenerative Medicine (CIRM) granted USD 32.3 million to researchers at City of Hope to fund three groundbreaking phase 1 clinical trials. These trials aim to assess novel cell and gene therapy treatments for patients dealing with HIV, acute myeloid leukemia, and severe aplastic anemia.

Market Concentration & Characteristics

The market growth stage is high, and pace of the market growth is accelerating. The market is characterized by a high degree of innovation owing to the rapid technological advancements driven by factors such as the use of CRISPR/Cas9* genome editing and the generation of genetically modified mouse.

The market is also characterized by a high level of merger and acquisition (M&A) activity undertaken by the leading players. This is due to several factors, the rising focus on increasing the company’s products & services portfolio, the need to consolidate in a rapidly growing market, and the increasing strategic importance of cell therapy. Several companies are undertaking this strategy to strengthen their portfolio. For instance, in January 2022, Thermo Fisher Scientific, Inc., acquired PeproTech, Inc., a major recombinant protein manufacturer. This acquisition strengthened the stem cells portfolio of Thermo Fisher Scientific, Inc.

The market is also subject to increasing regulatory scrutiny. Several regulatory and government authorities are focusing on establishing stringent guidelines for contamination control, biosafety, cell line authentication, and other factors. The growing focus towards cell therapy is projected to boost over the period of time.

Several companies are expanding their cell therapy -based products. Thus, the product expansion in this industry is significant. Companies are including product launches specifically targeting MSCs that are anticipated to drive market growth. For instance, in July 2023, PromoCell GmbH the company introduced a new product, PromoExQ MSC Growth Medium XF, for cell therapy manufacturing.

Product Insights

The cell culture supplements segment held the largest market share of 27.84% in 2023. The segment is divided into proteins, growth factors, nucleotides, and other supplements. Due to the rising demand for animal-free cell-based therapies, the segment is anticipated to grow during the forecast period. Numerous market participants are actively exploring untapped opportunities in the market through initiatives such as the development of new products & business expansion. Furthermore, growth factors hold the largest market share among cell culture supplements. Cell culture supplements provide a means to achieve serum-free conditions while maintaining the necessary growth factors and nutrients for robust cell growth. For instance, a study published in 2020 reported on the sequential delivery of cryogel-released growth factors & cytokines, which accelerated wound healing and improved tissue regeneration.

The cell culture media segment is expected to register the fastest CAGR over the forecast period. Cell culture media provides a controlled and optimized environment with essential nutrients, growth factors, and other critical components necessary for the survival & proliferation of cells. This controlled environment allows researchers and manufacturers to optimize conditions, ensuring the reproducibility & scalability of cell cultures for therapeutic applications. In addition, numerous companies are making substantial investments in the development of cell culture media to enhance the effectiveness of the cell therapy process. For instance, in May 2023, Lonza introduced TheraPEAK T-VIVO Cell Culture Medium to expedite the development of cell therapy.

End Use Insights

Based on end use, the market is segmented into biotechnology & pharmaceutical companies, CROs & CMOs, and others. The biopharmaceutical & pharmaceutical companies segment dominated the market with a share in 2023. This can be attributed to the increasing investments in R&D activities, rising demand for cell-based therapies, and the presence of advanced healthcare infrastructure. Owing to this, companies invest heavily in R&D, leveraging their expertise in biotechnology to discover & produce novel cell therapies. For instance, in May 2023, NewBiologix secured USD 50 million in funding to propel the development of its innovative technology platform dedicated to advancing the manufacturing processes of gene and cell therapies.

The CROs & CMOs segment is expected to register the fastest CAGR during the forecast period. Contract Research Organizations (CROs) offer valuable services in preclinical & clinical research, facilitating the development of cell therapies by providing expertise in trial design, patient recruitment, and regulatory compliance. On the other hand, Contract Manufacturing Organizations (CMOs) offer better and cost-effective manufacturing solutions to biopharmaceutical companies lacking the expertise. Thus, due to the provision of highly specialized services, CROs and CMOs have emerged as key players in the end use segment.

Regional Insights

North America dominated the market and accounted for 46.05 % share in 2023. The region's dominance can be attributed to supportive government regulations, growing demand for innovative therapeutics, and increasing efforts by key market players to advance cell-based therapy products for treating a range of chronic disorders. In addition, many leading companies involved in producing and commercializing cell-based products are based in North America, which is projected to boost the demand for cell therapy human raw materials, contributing to market growth. Moreover, collaborations between key players and smaller biotechnology firms intensify competition, as companies aim to strengthen their positions in the rapidly evolving cell therapy market. For instance, in January 2023, Kite, a subsidiary of Gilead, initiated a strategic collaboration with Arcellx, Inc., aiming to collaboratively develop and commercialize CART-ddBCMA for the treatment of relapsed multiple myeloma.

Asia Pacific is anticipated to witness fastest growth in the market from 2024 to 20230. This is attributed to the increasing focus on biotechnology and the rising demand for advanced cell therapies. Moreover, the key factors contributing to the market growth include a surge in R&D activities, strategic collaborations, and the establishment of manufacturing facilities by major players. For instance, as per an article published in TEIJIN CDMO in April 2023, Japan’s cell & gene therapies and regenerative medicines sector was recently valued at USD 185.5 million and is expected to grow to USD 6.3 million by 2030.

Key Companies & Market Share Insights

Some of the key players operating in the market include Charles River Laboratories, Thermo Fisher Scientific, Inc, Merck KGaA, Danaher, and Grifols, S.A.

•  Charles River Laboratories has a global presence, which is dedicated to offering comprehensive solutions in the realm of cell therapy and human raw materials, contributing significantly to advancements in this critical area of research and development.

• Merck KGaA, a leading entity in the industry, operates across numerous locations worldwide. The company is a key player in providing an overview of services related to cell therapy human raw materials. With a presence in multiple places, Merck KGaA is committed to delivering comprehensive solutions in the field of cell therapy and human raw materials, playing a crucial role in advancing research and development in this important area.

RoosterBio, Inc., Akron Biotech and AllCells. are some of the emerging market participants in the market.

• Akron Bio announced a cutting-edge plasmid DNA manufacturing facility in Sarasota, Florida, adhering to cGMP standards.

• AllCells provides several types of RUO and GMP products which are used in cell-based research activities and therapies

Recent Developments

• In July 2023, Merck KGaA invested USD 24.38 million to boost cell culture media production in the U.S. It expanded the production capacity of the Lenexa facility to manufacture cell culture media.

• In March 2023, Gemini Bio announced the launch of a modern cGMP bioprocess liquid manufacturing facility in West Sacramento, California. This enhanced its capabilities to meet the growing demands of biotechnology and cell & gene therapy markets.

• In November 2023, ACROBiosystems announced the release of GMP-grade DLL4. This recombinant, soluble form of Delta-like Ligand 4 (DLL4), used for the manufacturing of stem cells, is among the limited products in the market produced under GMP conditions.

 Cell Therapy Human Raw Materials Market Report Scope

Global Cell Therapy Human Raw Materials Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global rat and mouse model market report based on product, end-use, and region:

• Product Outlook (Revenue, USD Billion, 2018 - 2030)

  • Cell Culture Media

  • Cell Culture Sera

  • Cell Culture Supplements

    • Proteins

    • Growth Factors

    • Nucleotides

    • Other Supplements

  • Reagents & Buffers

  • Other Raw Materials

• End-Use Outlook (Revenue, USD Billion, 2018 - 2030)

  • Biopharmaceutical & Pharmaceutical Companies

  • CROs & CMOs

  • Academic & Research Institutions

• Regional Outlook (Revenue, USD Billion, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • Japan

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait